Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 315.00
Bid: 285.00
Ask: 345.00
Change: 0.00 (0.00%)
Spread: 60.00 (21.053%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 315.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: FTSE 100 as investors look to Fed rate decision

Mon, 29th Apr 2024 16:58

(Alliance News) - The FTSE 100 in London closed higher on Monday, outperforming its European counterparts, as investors eye this week's interest rate decision from the US Federal Reserve.

The FTSE 100 index closed up 7.20 points, 0.1%, at 8,147.03. The FTSE 250 ended up 260.63 points, 1.3%, at 20,084.79, and the AIM All-Share closed up 8.05 points, 1.1%, at 763.33.

The Cboe UK 100 ended up 0.1% at 814.08, the Cboe UK 250 closed up 1.2% at 17,335.92, and the Cboe Small Companies ended up 0.3% at 15,709.26.

In European equities on Monday, the CAC 40 in Paris was down 0.3% and the DAX 40 in Frankfurt closed down 0.2%.

On Monday, the FTSE 100 climbed to 8,189.14, its best-ever level, before falling after midday. In the year-to-date, the index is up 5.5%.

The Federal Reserve announces an interest rate decision on Wednesday. It is expected to leave rates unmoved, but with recent inflation readings coming in hot, and words from policymakers hawkish, focus will be on what Chair Jerome Powell has to say.

"Fed easing expectations have been pushed out. Odds of a June cut have fallen to around 10%, while July odds have fallen to 35% and September odds have fallen below 80%. A November cut is fully priced in, but the odds have fallen below 100% from time to time," analysts at Brown Brothers Harriman said.

US inflation pressure was hotter than expected last month, according to the Federal Reserve's preferred gauge released Friday.

The Bureau of Economic Analysis said the core personal consumption index gauge grew 2.8% in March, the annual pace of growth unmoved from February. In February, it had cooled slightly from 2.9% in January.

Stocks in New York were higher at the London equities close, with the DJIA, the S&P 500 index, and the Nasdaq Composite were all up 0.2%.

The pound was quoted at USD1.2554 at the London equities close Monday, higher compared to USD1.2453 at the close on Friday. The euro stood at USD1.0717 at the European equities close Monday, up against USD1.0676 at the same time on Friday.

However, against the yen, the dollar was trading at JPY156.64, lower compared to JPY157.41 late Friday.

In the FTSE 100, miner Anglo American added 3.8% amid growing conviction that it could receive another takeover bid.

Reuters reported BHP is mulling an improved bid for Anglo American. Citing a source, the news agency reported a sweetened offer could be made "in coming weeks". BHP last week Thursday confirmed it had offered to buy Anglo American in an all-share deal valuing the mining group at GBP31.1 billion. Anglo American rejected the offer.

"Investors have clearly spent the weekend sitting down with a cuppa and reading the papers as all the column inches about potential counter bids for Anglo American have got people reaching for the 'buy' button in their ISA or pension," said AJ Bell's Russ Mould.

Entain rose 2.1%, after it announced the repricing of two existing Term B loans, which it said will improve liquidity by about GBP295 million.

The Isle of Man-based bookmaker, which owns Ladbrokes and Coral, said the changes applied to a USD term loan worth USD1.74 billion, and a EUR term loan worth EUR1.03 billion.

In the FTSE 250, Playtech surged 12%.

The Isle of Man-based gambling software development company announced the expansion of its iPoker network into the Czech Republic, in partnership with Fortuna Entertainment Group.

"This launch represents a significant milestone for both Playtech and Fortuna, as it introduces poker into the Fortuna Entertainment Group for the first time. Through Playtech's iPoker network, Fortuna's players in the Czech Republic will now have access to a diverse range of poker games, benefitting from a strong international liquidity pool of players from all around the world, plus a high-quality player experience and state-of-the-art poker product," Playtech said.

Amongst London's small-caps, Oxford BioMedica shot up 10%.

The gene and cell-therapy company said it is seeing decent demand for its contract development and manufacturing organisation offering, as it moves away from the Covid-19 vaccine era.

Brent oil was quoted at USD87.27 a barrel at the London equities close Monday, down from USD88.26 late Friday.

Gold was quoted at USD2,337.40 an ounce at the London equities close Monday, higher against USD2,333.37 at the close on Friday.

In Tuesday's UK corporate calendar, there are first quarter results from HSBC, as well as full year results from Whitbread. There are trading statements from Coca-Cola HBC, Glencore, and Hargreaves Lansdown.

The economic calendar for Tuesday has a eurozone gross domestic product reading, as well as consumer price inflation data. There is unemployment data from Germany, alongside retail sales data.

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
28 Jan 2022 16:19

CORRECT: Oxford BioMedica to acquire 80% ownership of new US business

CORRECT: Oxford BioMedica to acquire 80% ownership of new US business

Read more
28 Jan 2022 12:13

LONDON MARKET MIDDAY: Stocks sink on Ukraine tensions and hawkish Fed

LONDON MARKET MIDDAY: Stocks sink on Ukraine tensions and hawkish Fed

Read more
28 Jan 2022 10:27

Oxford BioMedica to acquire 80% ownership of new US virus business

Oxford BioMedica to acquire 80% ownership of new US virus business

Read more
28 Jan 2022 09:56

Oxford Biomedica creates venture with Homology, launches £80m fundraise

(Sharecast News) - Cell and gene therapy specialist Oxford Biomedica announced an agreement with Homology Medicines on Friday, as well as a placing to raise £80m from new and existing shareholders, including a retail offer through the PrimaryBid platform.

Read more
17 Jan 2022 09:32

Oxford Biomedica starts search for new CEO as Dawson steps down

Oxford Biomedica starts search for new CEO as Dawson steps down

Read more
17 Jan 2022 07:10

Oxford Biomedica CEO John Dawson to step down

(Sharecast News) - Oxford Biomedica chief executive John Dawson said he was stepping down after 13 years at the helm of the Gene and cell therapy firm which helped develop a Covid-19 vaccine with AstraZeneca.

Read more
5 Jan 2022 08:54

Oxford Biomedica wins new agreement for LentiVector platform

Oxford Biomedica wins new agreement for LentiVector platform

Read more
5 Jan 2022 07:29

Oxford Biomedica signs licence, supply deal with Cabaletta Bio

(Sharecast News) - Gene and cell therapy group Oxford Biomedica on Wednesday said it had signed a new license and supply agreement on its LentiVector platform with US-based Cabaletta Bio.

Read more
15 Dec 2021 09:33

LONDON BROKER RATINGS: BofA starts Pod Point at Buy; Barclays cuts DCC

LONDON BROKER RATINGS: BofA starts Pod Point at Buy; Barclays cuts DCC

Read more
13 Dec 2021 10:03

Oxford Biomedica in license and supply deals with Novartis and Arcellx

Oxford Biomedica in license and supply deals with Novartis and Arcellx

Read more
13 Dec 2021 07:31

Oxford Biomedica strikes new license and supply agreements

(Sharecast News) - Gene and cell therapy group Oxford Biomedica has struck new license and supply agreements for its lentiviral vectors.

Read more
19 Oct 2021 10:50

Oxford BioMedica licences technology for cystic fibrosis treatment

Oxford BioMedica licences technology for cystic fibrosis treatment

Read more
19 Oct 2021 09:18

Boehringer Ingelheim licenses Oxford Biomedica's lentiviral vector technology

(Sharecast News) - Gene and cell therapy firm Oxford Biomedica said on Tuesday that pharmaceutical giant Boehringer Ingelheim had exercised its option to license its lentiviral vector technology to manufacture, register and commercialise a treatment for cystic fibrosis.

Read more
30 Sep 2021 09:35

LONDON BROKER RATINGS: Keppler Cheuvreux raises Pearson to Hold

LONDON BROKER RATINGS: Keppler Cheuvreux raises Pearson to Hold

Read more
28 Sep 2021 09:40

LONDON BROKER RATINGS: Investec prefers 888 over Entain

LONDON BROKER RATINGS: Investec prefers 888 over Entain

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.